High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy

mAbs

Volumn 6, Issue 2, 2014, Pages 483-492

  Liu, Yuqi ^a   Caffry, Isabelle ^a   Wu, Jiemin ^c   Geng, Steven B ^c   Jain, Tushar ^b   Sun, Tingwan ^a   Reid, Felicia ^a   Cao, Yuan ^a   Estep, Patricia ^a   Yu, Yao ^a   Vaśquez, Maximiliano ^b   Tessier, Peter M ^c   Xu, Yingda ^a  

^a Protein Analytics Adimab   (United States)

^b Computational Biology Adimab ^*  (United States)

^c Rensselaer Polytechnic Institute   (United States)

Author keywords

Aggregation; Antibody developability; Cross interaction; High throughput screening; Nanoparticle; Self association; Self interaction

Indexed keywords

GOLD NANOPARTICLE; IMMOBILIZED ANTIBODY; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

AFFINITY CAPTURE SELF INTERACTION NANOPARTICLE SPECTROSCOPY; ARTICLE; ASSAY; BIOLOGICAL ACTIVITY; HIGH THROUGHPUT SCREENING; MEASUREMENT; REPRODUCIBILITY; SPECTRAL SENSITIVITY; SPECTROSCOPY; VISCOSITY;

AGGREGATION; ANTIBODY DEVELOPABILITY; CROSS-INTERACTION; HIGH-THROUGHPUT SCREENING; NANOPARTICLE; SELF-ASSOCIATION; SELF-INTERACTION;

ANTIBODIES, IMMOBILIZED; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CELLS, CULTURED; DRUG DISCOVERY; GOLD; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOTHERAPY; METAL NANOPARTICLES; PROTEIN MULTIMERIZATION; REPRODUCIBILITY OF RESULTS; SPECTRUM ANALYSIS; SURFACE PLASMON RESONANCE;

EID: 84896520964     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27431     Document Type: Article

References (46)

1. Elvin JG, Couston RG, van der Walle CF. Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int J Pharm 2013; 440:83-98; PMID:22227342; http://dx.doi.org/10.1016/j.ijpharm.2011.12.039
2. TABS Therapeutic Antibody Database [Internet]. Available from: http://tabs.craic.com/
3. Drake AW, Papalia GA. Biophysical Considerations for Development of Antibody-Based Therapeutics. In: Tabrizi MA, Bornstein GG, Klakamp SL, editors. Development of Antibody-Based Therapeutics. New York, NY: Springer New York; 2012. page 95-139.
4. Yang X, Xu W, Dukleska S, Benchaar S, Mengisen S, Antochshuk V, Cheung J, Mann L, Babadjanova Z, Rowand J, et al. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies. MAbs 2013; 5:787-94; PMID:23883920; http://dx.doi.org/10.4161/mabs. 25269
5. Saxena V, Panicucci R, Joshi Y, Garad S. Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates. J Pharm Sci 2009; 98:1962-79; PMID:18855914; http://dx.doi.org/10. 1002/jps.21592
6. Sathish H, Angell N, Lowe D, Shah A, Bishop S. Application of Biophysics to the Early Developability Assessment of Therapeutic Candidates and Its Application to Enhance Developability Properties. In: Narhi LO, editor. Biophysics for Therapeutic Protein Development. Springer New York; 2013. page 127-46.
7. Connolly BD, Petry C, Yadav S, Demeule B, Ciaccio N, Moore JMR, Shire SJ, Gokarn YR. Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter. Biophys J 2012; 103:69-78; PMID:22828333; http://dx.doi.org/10.1016/j.bpj.2012. 04.047
8. Yadav S, Liu J, Shire SJ, Kalonia DS. Specific interactions in high concentration antibody solutions resulting in high viscosity. J Pharm Sci 2010; 99:1152-68; PMID:19705420; http://dx.doi.org/10.1002/jps.21898
9. Kanai S, Liu J, Patapoff TW, Shire SJ. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J Pharm Sci 2008; 97:4219-27; PMID:18240303; http://dx.doi.org/10.1002/jps.21322
10. Bethea D, Wu S-J, Luo J, Hyun L, Lacy ER, Teplyakov A, Jacobs SA, O'Neil KT, Gilliland GL, Feng Y. Mechanisms of self-association of a human monoclonal antibody CNTO607. Protein Eng Des Sel 2012; 25:531-7; PMID:22915597; http://dx.doi.org/10.1093/protein/gzs047
11. Wu S-J, Luo J, O'Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS, et al. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel 2010; 23:643-51; PMID:20543007; http://dx.doi.org/10.1093/protein/gzq037
12. Hötzel I, Theil F-P, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs 2012; 4:753-60; PMID:23778268; http://dx.doi.org/10.4161/mabs.22189
13. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI. High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 2010; 99:1707-20; PMID:19780136
14. He F, Woods CE, Becker GW, Narhi LO, Razinkov VI. High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations. J Pharm Sci 2011; 100:5126-41; PMID:21789772; http://dx.doi.org/10.1002/jps.22712
15. Esfandiary R, Hayes DB, Parupudi A, Casas-Finet J, Bai S, Samra HS, Shah AU, Sathish HA. A systematic multitechnique approach for detection and characterization of reversible self-association during formulation development of therapeutic antibodies. J Pharm Sci 2013; 102:3089-99; PMID:23794522; http://dx.doi.org/10.1002/jps.23654
16. Salinas BA, Sathish HA, Bishop SM, Harn N, Carpenter JF, Randolph TW. Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J Pharm Sci 2010; 99:82-93; PMID:19475558; http://dx.doi.org/10. 1002/jps.21797
17. Sahin E, Grillo AO, Perkins MD, Roberts CJ. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. J Pharm Sci 2010; 99:4830-48; PMID:20821389; http://dx.doi.org/10.1002/jps.22198
18. Sahin E, Weiss WF 4th, Kroetsch AM, King KR, Kessler RK, Das TK, Roberts CJ. Aggregation and pH-temperature phase behavior for aggregates of an IgG2 antibody. J Pharm Sci 2012; 101:1678-87; PMID:22246657; http://dx.doi.org/10. 1002/jps.23056
19. Roberts CJ, Das TK, Sahin E. Predicting solution aggregation rates for therapeutic proteins: approaches and challenges. Int J Pharm 2011; 418:318-33; PMID:21497188; http://dx.doi.org/10.1016/j.ijpharm.2011.03.064
20. Ahamed T, Ottens M, van Dedem GWK, van der Wielen LAM. Design of self-interaction chromatography as an analytical tool for predicting protein phase behavior. J Chromatogr A 2005; 1089:111-24; PMID:16130779; http://dx.doi.org/10.1016/j.chroma.2005.06.065
21. Bengali AN, Tessier PM. Biospecific protein immobilization for rapid analysis of weak protein interactions using self-interaction nanoparticle spectroscopy. Biotechnol Bioeng 2009; 104:240-50; PMID:19489026; http://dx.doi.org/10.1002/bit.22392
22. García CD, Hadley DJ, Wilson WW, Henry CS. Measuring protein interactions by microchip self-interaction chromatography. Biotechnol Prog 2003; 19:1006-10; PMID:12790668; http://dx.doi.org/10.1021/bp025788z
23. Johnson DH, Parupudi A, Wilson WW, DeLucas LJ. High-throughput self-interaction chromatography: applications in protein formulation prediction. Pharm Res 2009; 26:296-305; PMID:18923812; http://dx.doi.org/10.1007/s11095- 008-9737-6
24. Le Brun V, Friess W, Bassarab S, Mühlau S, Garidel P. A critical evaluation of self-interaction chromatography as a predictive tool for the assessment of protein-protein interactions in protein formulation development: a case study of a therapeutic monoclonal antibody. Eur J Pharm Biopharm 2010; 75:16-25; PMID:20102739; http://dx.doi.org/10.1016/j.ejpb.2010.01.009
25. Patro SY, Przybycien TM. Self-interaction chromatography: a tool for the study of protein-protein interactions in bioprocessing environments. Biotechnol Bioeng 1996; 52:193-203; PMID:18629888; http://dx.doi.org/10.1002/(SICI)1097- 0290(19961020)52:2〈193::AID-BIT2〉3.0.CO;2-L
26. Jacobs SA, Wu S-J, Feng Y, Bethea D, O'Neil KT. Cross-interaction chromatography: a rapid method to identify highly soluble monoclonal antibody candidates. Pharm Res 2010; 27:65-71; PMID:19911257; http://dx.doi.org/10.1007/ s11095-009-0007-z
27. Tessier PM, Sandler SI, Lenhoff AM. Direct measurement of protein osmotic second virial cross coefficients by cross-interaction chromatography. Protein Sci 2004; 13:1379-90; PMID:15075404; http://dx.doi.org/10.1110/ps.03419204
28. Spencer S, Bethea D, Raju TS, Giles-Komar J, Feng Y. Solubility evaluation of murine hybridoma antibodies. MAbs 2012; 4:319-25; PMID:22531448; http://dx.doi.org/10.4161/mabs.19869
29. Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu T-Y, Torrey J, Thomas J, Bobrowicz P, Vásquez M, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel 2013; 26:663-70; PMID:24046438; http://dx.doi.org/10.1093/protein/gzt047
30. Nishi H, Miyajima M, Wakiyama N, Kubota K, Hasegawa J, Uchiyama S, Fukui K. Fc domain mediated self-association of an IgG1 monoclonal antibody under a low ionic strength condition. J Biosci Bioeng 2011; 112:326-32; PMID:21783411; http://dx.doi.org/10.1016/j.jbiosc.2011.06.017
31. Sun T, Reid F, Liu Y, Cao Y, Estep P, Nauman C, Xu Y. High throughput detection of antibody self-interaction by bio-layer interferometry. MAbs 2013; 5:5; PMID:23995620; http://dx.doi.org/10.4161/mabs.26186
32. Perchiacca JM, Ladiwala ARA, Bhattacharya M, Tessier PM. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. Protein Eng Des Sel 2012; 25:591-601; PMID:22843678; http://dx.doi.org/10.1093/protein/gzs042
33. Perchiacca JM, Tessier PM. Engineering aggregation-resistant antibodies. Annu Rev Chem Biomol Eng 2012; 3:263-86; PMID:22468604; http://dx.doi.org/10. 1146/annurev-chembioeng-062011-081052
34. Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci U S A 2012; 109:10879-84; PMID:22745168; http://dx.doi.org/10.1073/pnas.1202866109
35. Wang X, Singh SK, Kumar S. Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis. Pharm Res 2010; 27:1512-29; PMID:20422267; http://dx.doi.org/10.1007/s11095-010-0143-5
36. Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, Walus L, Eldredge J, Capili A, Mi S, Graff C, et al. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci 2010; 19:954-66; PMID:20198683
37. Saluja A, Fesinmeyer RM, Hogan S, Brems DN, Gokarn YR. Diffusion and sedimentation interaction parameters for measuring the second virial coefficient and their utility as predictors of protein aggregation. Biophys J 2010; 99:2657-65; PMID:20959107; http://dx.doi.org/10.1016/j.bpj.2010.08.020
38. Sule SV, Dickinson CD, Lu J, Chow C-K, Tessier PM. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. Mol Pharm 2013; 10:1322-31; PMID:23383873; http://dx.doi.org/10.1021/mp300524x
39. th, Marcelino-Cruz AM, Sample T, Tessier PM. High-throughput analysis of concentration-dependent antibody self-association. Biophys J 2011; 101:1749-57; PMID:21961601; http://dx.doi.org/10.1016/j.bpj.2011.08.036
40. Tessier PM, Jinkoji J, Cheng Y-C, Prentice JL, Lenhoff AM. Self-interaction nanoparticle spectroscopy: a nanoparticle-based protein interaction assay. J Am Chem Soc 2008; 130:3106-12; PMID:18271584; http://dx.doi.org/10.1021/ja077624q
41. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human antitumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48:35-45; PMID:12528101; http://dx.doi.org/10.1002/art. 10697
42. Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett 2006; 27:861-74; http://dx.doi.org/10.1016/j.patrec.2005.10.010
43. Rohani MM, Zydney AL. Role of electrostatic interactions during protein ultrafiltration. Adv Colloid Interface Sci 2010; 160:40-8; PMID:20688310; http://dx.doi.org/10.1016/j.cis.2010.07.002
44. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin C-C, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009; 27:5800-7; PMID:19786654; http://dx.doi.org/10.1200/JCO.2009.23.6745
45. NCT01843374 - Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma [Internet]. Available from: http://clinicaltrials.gov/show/NCT01843374
46. NCT00747734 - A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors [Internet]. Available from: http://clinicaltrials.gov/ ct2/show/NCT00747734